

Remarks

Applicants have amended the claims to recite SEQ ID NOs, and have amended the Sequence Listing. Applicants' Agent hereby states that the changes made in the Sequence Listing do not include new matter. In compliance with 37 C.F.R. § 1.825(a), Applicants submit substitute sheets to amend the paper copy of the Sequence Listing.

Applicants have corrected the definitions of the "Xaa" amino acids to specify the proper positions. Applicants have also added the sequences recited in claim 176 solely for the convenience of the Examiner, and not in acquiescence to the Notice To Comply dated April 30, 2002. The Substitute Sequence Listing is in post July 1998 format, and a CPA of the present application was filed February 13, 2002. Therefore the present application is subject to post July 1998 sequence rules. None of the sequences in Figures 1 and 2 contain four or more defined amino acid residues. Consequently they need not be included in the sequence listing. Applicants' undersigned agent has amended the specification to direct the entry of this substitute Sequence Listing at the end of the application.

In accordance with 37 C.F.R. § 1.825(b), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith are the same.

It is respectfully believed this application is now in condition for allowance. Early notice to this effect is earnestly solicited.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Helene C. Carlson
Agent for Applicants
Registration No. 47,473

Date: July 1, 2002

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

::ODMA\MHODMA\SKGF_DC1;25429;3

SKGF Rev. 1 1/26/01 mac

Version with markings to show changes made

In the Specification:

The paragraph beginning on page 1, line 8 was replaced with the following paragraph.

This application is a continuation-in-part of ~~related to~~ application U.S. Serial No. 08/344,824, filed November 23, 1994, and is a continuation-in-part of ~~related to~~ application U.S. Serial No. 08/278,634, filed July 21, 1994, both of which are incorporated herein by reference.

In the Claims:

The following claims 176, 201-209, and 232-233 were substituted for pending claims 176, 201-209, and 232-233.

176. (Once amended) A method of binding a human leukocyte antigen (HLA)-B7 molecule with a peptide comprising an epitope of p53, comprising:

- (a) contacting said HLA-B7 molecule with a peptide comprising a Proline (P) at position two of said peptide, and a Leucine (L) or an Isoleucine (I) at the carboxyl terminus of said peptide, wherein said peptide is 8-11 amino acids in length and comprises an epitope of p53 (SEQ ID NOS:31-34); and thereby
- (b) binding said HLA-B7 molecule and said peptide.

201. (Once Amended) The method of claim 177 ~~178~~, wherein said epitope is selected from the group consisting of: LPENNVLSPL (SEQ ID NO:13), APAPAPSWPL (SEQ ID

NO:14), SPALNKMFCQL (SEQ ID NO:15), RPILTIITL (SEQ ID NO:17), LPPGSTKRAL (SEQ ID NO:18), SPQPKKKPL (SEQ ID NO:19), and KPLDGEYFTL (SEQ ID NO:20).

202. (Once amended) The method of claim 201, wherein said epitope is LPENNVLSPL (SEQ ID NO:13).

203. (Once amended) The method of claim 201, wherein said epitope is APAPAPSWPL (SEQ ID NO:14).

204. (Once amended) The method of claim 201, wherein said epitope is SPALNKMFCQL (SEQ ID NO:15).

205. (Once amended) The method of claim 201, wherein said epitope is RPILTIITL (SEQ ID NO:17).

206. (Once amended) The method of claim 201, wherein said epitope is LPPGSTKRAL (SEQ ID NO:18).

207. (Once amended) The method of claim 201, wherein said epitope is SPQPKKKPL (SEQ ID NO:19).

208. (Once amended) The method of claim 201, wherein said epitope is KPLDGEYFTL (SEQ ID NO:20).

209. (Once amended) A method of binding a human leukocyte antigen (HLA)-B7 molecule with a peptide comprising an epitope of p53, comprising:

- (a) contacting said HLA-B7 molecule with a peptide comprising an epitope selected from the group consisting of: GTRVRAMAI (SEQ ID NO:16) and GSRAHSSHL (SEQ ID NO:21); wherein said peptide is 8-11 amino acids in length; and thereby
- (b) binding said HLA-B7 molecule and said peptide.

232. (Once amended) The method of claim 209, wherein said epitope is GTRVRAMAI (SEQ ID NO:16).

233. (Once amended) The method of claim 209, wherein said epitope is GSRAHSSHL (SEQ ID NO:21).